KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) Return on Capital Employed (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Return on Capital Employed for 12 consecutive years, with 0.09% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Capital Employed rose 27.0% to 0.09% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.09%, a 27.0% increase, with the full-year FY2025 number at 0.08%, up 25.0% from a year prior.
  • Return on Capital Employed was 0.09% for Q4 2025 at Xenon Pharmaceuticals, up from 0.57% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.04% in Q1 2022 to a low of 0.57% in Q3 2025.
  • A 5-year average of 0.24% and a median of 0.25% in 2021 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: fell -26bps in 2021, then grew 27bps in 2025.
  • Xenon Pharmaceuticals' Return on Capital Employed stood at 0.05% in 2021, then crashed by -230bps to 0.17% in 2022, then plummeted by -56bps to 0.27% in 2023, then plummeted by -32bps to 0.36% in 2024, then skyrocketed by 75bps to 0.09% in 2025.
  • Per Business Quant, the three most recent readings for XENE's Return on Capital Employed are 0.09% (Q4 2025), 0.57% (Q3 2025), and 0.47% (Q2 2025).